Splash Partners Lupvindol for CannEpil Veterinary Drug Development
Splash Beverage Group announced a strategic development and collaboration agreement with Lupvindol Biosciences Ltd. to advance CannEpil® as a potential FDA-regulated veterinary pharmaceutical product. The program will initially target companion-animal oncology and chronic pain management, with Splash retaining ownership of all resulting data, intellectual property, and commercialization rights. Lupvindol will lead the scientific and regulatory activities, while Splash provides milestone-based funding and manages commercialization strategy. This collaboration aims to leverage the significant opportunity in the companion-animal health market, which includes a veterinary pain management market projected to reach $3.8 billion by 2030.
Key Highlights
- Splash Beverage Group entered a strategic development and collaboration agreement with Lupvindol Biosciences Ltd.
- The partnership aims to advance CannEpil® as a potential FDA-regulated veterinary pharmaceutical product.
- Initial focus is on companion-animal oncology and chronic pain management, starting with canine applications.
- Splash retains ownership of resulting data, intellectual property, and commercialization rights.
- Lupvindol will lead scientific, product development, and FDA regulatory activities, including INAD submission.
- Splash will provide milestone-based funding and lead commercialization strategy and capital-markets activities.
- The global veterinary pain management market was valued at approximately $2.6 billion in 2024 and is projected to reach $3.8 billion by 2030.
Price Impact
More from SBEV